SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple shares are trending as investors focus on the official leadership transition to incoming CEO John Ternus and anticipation for the upcoming iPhone product event. While the stock has seen upward momentum, traders are actively debating its valuation, the potential impact of new product launches, and the company's broader AI strategy.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending as investors remain focused on strong demand for its AI-optimized servers ahead of the company's upcoming earnings report. The stock's recent performance is being bolstered by positive industry read-throughs, including bullish results from competitors in the AI infrastructure space.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Discussion is fragmented with no single finance-related catalyst; traders are primarily exchanging intense political criticism regarding company leadership, ongoing geopolitical tensions, and concerns over economic policies and inflation.

Fervo Energy Co. operates as a energy company. It builds and operates power facilities in extracting geothermal energy. The company was founded by Jack Norbeck and Timothy Latimer in 2017 and is headquartered in Berkeley, CA.

Fervo Energy Co. - Ordinary Shares - Class A

Fervo Energy Co

Fervo Energy is trending following the announcement of its largest power purchase agreement to date with Google, which serves as a major commercial validation for its enhanced geothermal strategy. While retail sentiment has turned strongly bullish and some traders are focused on the deal's potential to accelerate the company's project development, others express caution regarding the stock's valuation, lack of immediate profitability, and the broader volatility of its post-IPO performance.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as traders react to a volatile market environment characterized by rising Treasury yields, escalating geopolitical tensions in the Middle East, and concerns over the economic impact of sustained inflation. Discussion is heavily divided between bears anticipating a deeper correction due to these macro headwinds and bulls viewing recent dips as buying opportunities, with some questioning the sustainability of current tech valuations.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Investors are focused on Navitas' strategic acquisition of Claros, which is seen as a move to complete its power delivery stack and expand its total addressable market. While the deal is viewed as a bullish long-term development for AI infrastructure, sentiment remains tempered by broader market volatility, concerns over dilution, and ongoing patent litigation.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is attracting investor attention due to its strong financial position, including consistent profitability, a robust balance sheet, and ongoing share buyback programs, which traders frequently contrast with peers in the sector. Discussion is centered on anticipation of federal rescheduling catalysts and potential major exchange uplisting, which many in the community believe will serve as a major inflection point for the stock.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is trending as market participants debate its valuation and technical outlook ahead of its upcoming fiscal first-quarter earnings report. Investors are focused on whether strong hyperscaler demand for high-speed connectivity will drive a beat-and-raise performance, while some express concern over market volatility and sector-wide weakness.

Deere & Co. engages in the manufacture and distribution of equipment used in agriculture, construction, forestry, and turf care. It operates through the following segments: Agriculture and Turf, Construction and Forestry, and Financial Services. The Agriculture and Turf segment focuses on the distribution and manufacture of a full line of agriculture and turf equipment and related service parts. The Construction and Forestry segment offers machines and service parts used in construction, earthmoving, road building, material handling and timber harvesting. The Financial Services segment finances sales and leases by John Deere dealers of new and used agriculture and turf equipment and construction and forestry equipment. The company was founded by John Deere in 1837 and is headquartered in Moline, IL.

Deere & Co.

Deere & Co

Deere & Co is trending as traders capitalize on bullish momentum following better-than-expected earnings results, raised profit guidance, and positive sentiment regarding an agricultural cycle bottom. The community is actively discussing high-confidence call option setups and breakout potential for the stock to reach new all-time highs.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as traders speculate on upcoming clinical data for the obesity drug VK2735, with the community closely monitoring for updates from the phase 3 maintenance study. Enthusiasm is driven by expectations that the drug could offer best-in-class efficacy, leading to debate regarding potential partnership or acquisition scenarios.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Truist on $CYTK (Buy; $112) said -- We reiterate our Buy for CYTK following detailed ACACIA analyses at ESC this past weekend. 
$EWTX $BMY TECX TENX AZN NVO BAYRY 
Truist added—Despite ACACIA&#39;s imbalance in heart failure (4.7% vs. 1.2% pbo), we see a sizable and under-appreciated opportunity with Myqorzo in HCM (we model $5.8B in WW peak rev, 2036E). 
 
KOL checks highlight HF as a known side effect of CMIS, ACACIA had no afi-related deaths, improved HF rates with real-world-like use (FOREST-HCM). 
 
We believe Myqorzo will likely become the first approved therapy for nHCM (possibly with different REMS vs. oHCM) making it the only approved therapy for all of HCM, with potential to promote its use case over oHCM-only CMIs. 
 
We reiterate our Buy rating and $112 PT.

H.C. Wainwright reiterated $CYTK Buy-$140 and said Re: the $BMY litigation: we do not expect it to affect the drug&#39;s ongoing commercial momentum, with the product continuing to gain traction following its launch. 
$EWTX TECX TENX NVO BAYRY Medera - $KVACF  
Here&#39;s what H.C. Wainwright said in its note: https://x.com/Quantumup1/status/2088221120008765890?s=20

H.C. Wainwright reiterated $CYTK Buy-$140 and said Re: the $BMY litigation: we do not expect it to affect the drug's ongoing commercial momentum, with the product continuing to gain traction following its launch.$EWTX TECX TENX NVO BAYRY Medera - $KVACFH.C. Wainwright said --... https://t.co/IHT1fJlRn4

quantumup on X (formerly Twitter): "H.C. Wainwright reiterated $CYTK Buy-$140 and said Re: the $BMY litigation: we do not expect it to affect the drug's ongoing commercial momentum, with the product continuing to gain traction following its launch.$EWT...

StockTwits Web

Cytokinetics Inc

Bristol-Myers Squibb Co.

Edgewise Therapeutics Inc

Quantumup

 (Buy; $112) said -- We reiterate our Buy for CYTK following detailed ACACIA analyses at ESC this past weekend. 


 TECX TENX AZN NVO BAYRY 
Truist added—Despite ACACIA's imbalance in heart failure (4.7% vs. 1.2% pbo), we see a sizable and under-appreciated opportunity with Myqorzo in HCM (we model $5.8B in WW peak rev, 2036E). 
 
KOL checks highlight HF as a known side effect of CMIS, ACACIA had no afi-related deaths, improved HF rates with real-world-like use (FOREST-HCM). 
 
We believe Myqorzo will likely become the first approved therapy for nHCM (possibly with different REMS vs. oHCM) making it the only approved therapy for all of HCM, with potential to promote its use case over oHCM-only CMIs. 
 
We reiterate our Buy rating and $112 PT.